Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients

PURPOSE: Immune checkpoint blockade therapy is the standard treatment for metastatic or refractory non-small cell lung cancer (NSCLC). However, it is associated with immune-related adverse events (irAEs). irAEs are sometimes fatal; however, an efficient method for early irAEs detection has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Higashiyama, Ryoko Inaba, Horinouchi, Hidehito, Kuchiba, Aya, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314872/
https://www.ncbi.nlm.nih.gov/pubmed/35900471
http://dx.doi.org/10.1007/s00432-022-04205-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314872/
https://www.ncbi.nlm.nih.gov/pubmed/35900471
http://dx.doi.org/10.1007/s00432-022-04205-9

Ejemplares similares